HeartFlow announced today that it surpassed 250,000 patients receiving its FFRCT Analysis for non-invasively diagnosing coronary artery disease.
FFRCT Analysis and coronary computed tomography angiography (CCTA), provide an alternative to traditional ischemia testing methods. These methods include stress EKG, stress ECG, SPECT, PET and more. According to HeartFlow, these methods can result in false negatives 20%-30% of the time.
HeartFlow’s method non-invasively diagnoses CAD and offers guidance on subsequent treatment decisions. The AI-powered technology provides insights into each patient’s condition with a patient-specific model of the heart’s blood flow. It serves customers reliably with a median turnaround time registering less than 1.5 hours.
With its 250,000 patient cases, HeartFlow has partnerships with 1,000 global hospitals. That includes 80% of the top-50 heart hospitals in the U.S., according to a news release. The company also released its Plaque Analysis FDA-cleared technology this past year. It also launched its RoadMap Analysis for identifying and quantifying narrowing in the coronary arteries.
“We are extremely proud of achieving the 250,000 patient milestone with our physician partners. Our collective team shares in our excitement for the future and are eager to build on this success,” said John Farquhar, CEO at HeartFlow. “We’ve experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap Analysis. Our continued commitment to developing a new standard of care for patients at risk of heart disease remains steadfast and we look forward to surpassing more milestones in the future.”
